SEC Tracker
Get the app
CPMV · XBRL financial data

Mosaic ImmunoEngineering financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CPMV's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development8550*67614016*16161616*1616
General and administrative227226*201214147134*159133128132*139141
Total operating expenses312276*269274186150*175149144148*155157
Operating income (loss)(312)(276)*(269)(274)(186)(150)*(175)(149)(144)(148)*(155)(157)
Interest expense00*0033*2233*22
Income tax expense (benefit)00*0002*0200*00
Net income (loss)(333)(296)*(288)(294)(187)(153)*(181)(172)(165)(169)*(175)(177)
Earnings per share, basic USD per share(0.05)(0.04)*(0.04)(0.04)(0.03)(0.02)*(0.03)(0.02)(0.02)(0.02)*(0.02)(0.02)
Earnings per share, diluted USD per share(0.05)(0.05)*(0.04)(0.04)(0.03)(0.02)*(0.03)(0.02)(0.02)—(0.02)(0.02)
Weighted average shares, basic thousands of shares7,2367,236*7,2367,2367,2367,236*7,2367,2367,2367,236*7,2367,236
Weighted average shares, diluted thousands of shares7,2365,918*7,2367,2367,2367,236*7,2367,2367,236—7,2367,236

Balance sheet

CSV

Fiscal quarters (CPMV's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2531566546115865432400
Prepaid and other current assets—————27———16103
Total current assets28618079124014298585520103
Total assets28618079124014298585520103
Accounts payable116118129125144135138134134133167183
Accrued liabilities649642632624654647642637658655652671
Total current liabilities4,5694,7334,8965,1055,3015,5375,6575,7705,9156,0306,1776,330
Total liabilities5,8676,0516,2346,4616,6756,9307,0677,1997,3627,4967,6617,832
Accumulated deficit(7,621)(7,916)(8,205)(8,499)(8,685)(8,838)(9,020)(9,192)(9,357)(9,526)(9,702)(9,879)
Total stockholders' equity(5,581)(5,871)(6,155)(6,448)(6,635)(6,788)(6,969)(7,142)(7,307)(7,476)(7,651)(7,829)
Total liabilities and equity28618079124014298585520103
Common shares outstanding (cover page) thousands of shares7,2427,2427,2427,2427,2427,2427,2427,2427,2427,2427,2427,242

Cash flows

CSV

Fiscal quarters (CPMV's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(333)(296)*(288)(294)(187)(153)*(181)(172)(165)(169)*(175)(177)
Stock-based compensation66*5000*00*0*0*00*
Net cash from operating activities(110)*(97)*(91)(116)*(13)*(21)*(29)(32)*(22)*(28)*(4)(0)*
Net cash from investing activities0*0*00*0*0*——————
Proceeds from long-term debt0*0*——15*200*——0*0*——
Net cash from financing activities0*0*——15*130*——0*0*——

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Mosaic ImmunoEngineering0not reported(0)*7.2M0.6 quarters 10-QJun 30, 2026
China Foods Holdings160(94)*20.3M0.2 quarters 10-QJun 30, 2026
Hepion Pharmaceuticals1,629not reported(1,394)*90.2M1.2 quarters 10-QJun 30, 2026
Twinlab Consolidated Holdings13not reported(907)*259.1M0.0 quarters 10-KDec 31, 2024
Nutra Pharmanot reported34(251)*7.2B0.1 quarters 10-QJun 30, 2026
Regen BioPharma0.259(24)*1.7B0.0 quarters 10-QJun 30, 2026
Evofem Biosciences2852,633(3,140)*132.5M0.1 quarters 10-QJun 30, 2026
International Stem Cell1,0892,675167*8.0M— 10-QJun 30, 2026
Emmaus Life Sciences2,8086,3181,693*70.2M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.